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ABSTRACT
OBJECTIVE
To assess the benefits and harms of spinal 
manipulative therapy (SMT) for the treatment of 
chronic low back pain.
DESIGN
Systematic review and meta-analysis of randomised 
controlled trials.
DATA SOURCES
Medline, PubMed, Embase, Cochrane Central Register 
of Controlled Trials (CENTRAL), CINAHL, Physiotherapy 
Evidence Database (PEDro), Index to Chiropractic 
Literature, and trial registries up to 4 May 2018, 
including reference lists of eligible trials and related 
reviews.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Randomised controlled trials examining the effect of 
spinal manipulation or mobilisation in adults (≥18 
years) with chronic low back pain with or without 
referred pain. Studies that exclusively examined 
sciatica were excluded, as was grey literature. No 
restrictions were applied to language or setting.
REVIEW METHODS
Two reviewers independently selected studies, 
extracted data, and assessed risk of bias and quality 
of the evidence. The effect of SMT was compared 
with recommended therapies, non-recommended 
therapies, sham (placebo) SMT, and SMT as an 
adjuvant therapy. Main outcomes were pain and 
back specific functional status, examined as mean 
differences and standardised mean differences 
(SMD), respectively. Outcomes were examined at 1, 
6, and 12 months. Quality of evidence was assessed 
using GRADE. A random effects model was used and 
statistical heterogeneity explored.
RESULTS
47 randomised controlled trials including a total 
of 9211 participants were identified, who were 
on average middle aged (35-60 years). Most trials 
compared SMT with recommended therapies. 
Moderate quality evidence suggested that SMT has 
similar effects to other recommended therapies for 
short term pain relief (mean difference −3.17, 95% 
confidence interval −7.85 to 1.51) and a small, 
clinically better improvement in function (SMD 
−0.25, 95% confidence interval −0.41 to −0.09). 
High quality evidence suggested that compared 
with non-recommended therapies SMT results in 
small, not clinically better effects for short term pain 
relief (mean difference −7.48, −11.50 to −3.47) and 
small to moderate clinically better improvement in 
function (SMD −0.41, −0.67 to −0.15). In general, 
these results were similar for the intermediate and 
long term outcomes as were the effects of SMT as an 
adjuvant therapy. Evidence for sham SMT was low 
to very low quality; therefore these effects should 
be considered uncertain. Statistical heterogeneity 
could not be explained. About half of the studies 
examined adverse and serious adverse events, but 
in most of these it was unclear how and whether 
these events were registered systematically. Most of 
the observed adverse events were musculoskeletal 
related, transient in nature, and of mild to moderate 
severity. One study with a low risk of selection bias 
and powered to examine risk (n=183) found no 
increased risk of an adverse event (relative risk 1.24, 
95% confidence interval 0.85 to 1.81) or duration of 
the event (1.13, 0.59 to 2.18) compared with sham 
SMT. In one study, the Data Safety Monitoring Board 
judged one serious adverse event to be possibly 
related to SMT.
CONCLUSION
SMT produces similar effects to recommended 
therapies for chronic low back pain, whereas 
SMT seems to be better than non-recommended 
interventions for improvement in function in the  
short term. Clinicians should inform their patients  
of the potential risks of adverse events associated 
with SMT.
Introduction
Low back pain is a common and disabling disorder.1 
Adequate treatment of low back pain is therefore 
important for patients, clinicians, and healthcare 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Numerous randomised controlled trials of varying methodological quality and 
size have examined the benefits and harms of spinal manipulative therapy (SMT) 
for the treatment of chronic low back pain
These trials have been summarised in numerous systematic reviews with varying 
results
SMT is not currently recommended as a first line treatment for chronic low back 
pain and its effects are uncertain
WHAT THIS STUDY ADDS
SMT has similar effects to recommended therapies for chronic low back pain, 
although it seems to be better for short term improvement in function
Data for the other comparisons (placebo SMT and SMT as adjuvant therapy) 
might be considered less robust and therefore unclear
Information is limited on the incidence of adverse events and serious adverse 
events with SMT for this population
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policy makers. Spinal manipulative therapy (SMT) 
is widely used to treat low back pain and has been 
examined in numerous randomised controlled trials 
of varying methodological quality and size, with 
varying results. These trials have been summarised in 
systematic reviews, including an earlier review of ours, 
and the results form the basis for recommendations in 
clinical guidelines.2-5
The effectiveness of SMT for the treatment of chronic 
low back pain and therefore recommendations in 
international guidelines for the use of non-drug 
interventions in the treatment of non-specific 
low back pain, are not without dispute.6 In some 
countries, SMT is considered a first line treatment 
option,3 whereas in others it is recommended as a 
component of a broader treatment package including 
exercise,5 or is not included or mentioned at all.4 The 
most recent summary of these guidelines suggests 
that SMT should be considered a second line or 
adjuvant treatment option, after exercise or cognitive 
behavioural therapy.7
In this review, we consider SMT to represent any 
hands-on treatment of the spine, including both 
mobilisation and manipulation. Mobilisations use 
low grade velocity, small or large amplitude passive 
movement techniques within the patient’s range of 
motion and control, whereas manipulation uses a 
high velocity impulse or thrust applied to a synovial 
joint over a short amplitude at or near the end of the 
passive or physiological range of motion.8 This is often 
accompanied by an audible crack, resulting from 
cavitation of the joint.
Many hypotheses about how SMT might work 
exist.9 10 The modes of action can be roughly divided 
into biomechanical and neurophysiological. The 
mechanistic (biomechanical) approach suggests that 
SMT acts on a manipulable or functional spinal lesion; 
the treatment is designed to reduce internal mechanical 
stresses.11 12 The neurophysiological approach 
suggests that SMT affects the primary afferent neurons 
from paraspinal tissues, the motor control system, and 
pain processing.13-18
To resolve the issue of effectiveness, we conducted a 
systematic review and meta-analysis. This publication 
is an update of our earlier Cochrane review, which 
found high quality evidence suggesting no clinically 
relevant difference between SMT and effective 
interventions for reducing pain and improving function 
in patients with chronic low back pain.19 Data for the 
other comparisons were of lesser quality.
The primary objective of this current review was to 
examine the effectiveness of SMT on pain relief and 
improvement in function at the short, intermediate, and 
long term follow-up compared with control treatments 
for adults with chronic low back pain. Secondary 
objectives included the assessment of adverse events. 
The effect of SMT for other secondary outcomes, such 
as recovery, return to work, and health related quality 
of life are to be fully described elsewhere as an update 
of this review and published in the Cochrane Library.
Methods
This review follows the guidelines for Preferred 
Reporting Items for Systematic reviews and Meta-
analyses (PRISMA). Our protocol is registered with the 
Cochrane Collaboration.20
Criteria for considering studies for this review
We only included published randomised studies. 
Studies using an inadequate randomisation procedure 
(eg, alternate allocation, allocation based on birth 
date) were excluded, as was grey literature.
Studies were considered eligible if they included 
adults (≥18 years) and if more than 50% of the study 
population had pain lasting more than three months. 
Additionally, we included studies if the observed 
differences were thought to be due to the unique 
contribution of SMT, which may include studies in 
which SMT was delivered as part of a package of 
care—that is, if the effects of SMT could be isolated; for 
example, studies comparing SMT plus exercise with 
exercise alone would be included, whereas studies 
comparing SMT plus exercise with SMT alone would not. 
We excluded participants with postpartum low back 
pain or pelvic pain due to pregnancy, pain unrelated 
to the lower back, postoperative studies, patients 
with serious pathology, and studies that examined 
“maintenance care” or prevention; in addition to 
studies that were designed to test the immediate post-
intervention effect of a single treatment only as well as 
those studies that exclusively examined back related 
conditions (eg, sciatica). We also excluded studies if 
SMT was combined with other therapies, making it 
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difficult to distinguish the effect of SMT—for example, 
a study comparing SMT plus exercise with another type 
of treatment (eg, general practitioner care).
This review focuses on the effects of both spinal 
manipulation (high velocity, low amplitude (HVLA) 
techniques) as well as mobilisation (low velocity, low 
amplitude (LVLA) techniques).
Primary analyses
We examined the effect of SMT compared with 
recommended therapies, non-recommended therapies, 
sham (placebo) SMT, and SMT as adjuvant therapy to 
any other therapy. Sham SMT was any comparator in 
which SMT involved hand contact, active or passive 
range of motion, or both, and techniques that simulated 
SMT but was designed not to deliver a therapeutic effect 
(eg, light touch or diminished therapeutic force), or 
even improper care (eg, improper patient positioning 
or purposely misdirected movements).
Secondary analyses
Although we considered the effect of HVLA SMT versus 
LVLA SMT (ie, manipulation versus mobilisation) as 
secondary because it was not included in our protocol, 
we included this comparison as it represents a point of 
continued discussion.
We based the determination of recommended 
and non-recommended interventions on recent 
international low back pain guidelines from the 
United States,3 United Kingdom,5 and Netherlands.4 
An intervention was categorised into recommended 
or non-recommended when this was stated in two or 
more of these guidelines. The recommended control 
therapies examined in this review included non-drug 
(eg, exercise) and drug treatments (eg, non-steroidal 
anti-inflammatory drugs, analgesics), whereas non-
recommended interventions included non-effective 
(eg, light soft tissue massage, no treatment, waiting 
list control) or potentially even harmful treatments (eg, 
electrotherapies). When evidence conflicted, or the 
recommendation was not clear from these guidelines 
(eg, acupuncture), we consulted other guidelines, such 
as the COST B13 European guidelines.2
Outcome measures
The primary outcomes were pain intensity and back 
pain specific functional status. Adverse events and 
serious adverse events are summarised narratively.
Search methods for identification of studies
We identified randomised controlled trials from 
an electronic search of several databases (up to 4 
May 2018): Cochrane Central Register of Controlled 
Trials (CENTRAL), Medline, Medline In-Process and 
Other Non-Indexed Citations, Embase, CINAHL, 
Physiotherapy Evidence Database (PEDro), Index to 
Chiropractic Literature, and PubMed. An experienced 
information specialist carried out the searches 
according to the recommendations of the Cochrane 
Handbook.21 In addition, we also screened the reference 
lists of all included studies and systematic reviews; 
searched trial registers, specifically, ClinicalTrials.gov 
and World Health Organization International Clinical 
Trials Registry Platform (ICTRP); and we sent our 
selection of studies to trial authors and specialists in 
SMT to identify any trials potentially missed. Appendix 
1 shows the search terms and strategies.
Data collection and analysis
Two review authors (SMR, AdeZ) independently 
screened the titles and abstracts, evaluated the risk of 
bias, extracted data, and assessed the quality of the 
evidence (GRADE). Consensus was reached during 
meetings. Potentially relevant studies were obtained in 
full text and independently assessed for inclusion. Only 
full papers were evaluated. No language restrictions 
were applied.
Data extraction and management—A standardised 
form was used to extract the study design (randomised 
controlled trial), study and population characteristics, 
intervention and control characteristics, outcome 
measures, and follow-up intervals, as well other 
relevant data, such as source of funding, authors’ 
declaration of interests, and risk of bias. Final value 
scores (means and standard deviations) were extracted 
for the meta-analyses. Change scores were converted 
into a mean value.
Assessment of risk of bias in included studies—
risk of bias was assessed according to the 13 criteria 
recommended by the Cochrane Back and Neck Review 
Group (see appendix 2). This tool is the same as that 
recommended by the Cochrane Collaboration, with 
the addition of items thought to be relevant in the 
assessment of non-drug trials, such as compliance, 
use of co-interventions, similarities of the groups 
at baseline, use of intention-to-treat analysis, and 
“other” (eg, potential conflicts of interest). We used 
this tool to evaluate selection bias, performance 
bias, detection bias, attrition bias, selective outcome 
reporting bias, and any other forms of bias, such as 
conflicts of interest. These criteria were scored as 
low risk, high risk, or unclear risk. Studies with fatal 
flaws were excluded from the meta-analyses, defined 
as studies with an exceedingly large drop-out rate or 
with statistically and clinically relevant important 
baseline differences, suggesting possibly improper 
randomisation or selective exclusion of data.
Measures of treatment effect—Pain is expressed 
as mean difference and functional status as a 
standardised mean difference (SMD), including 95% 
confidence intervals. All pain scales were converted 
to a 100 point scale. A negative effect size indicates 
that SMT is more beneficial than the comparison 
therapy; meaning that participants have less pain or 
better functional status. A random effects model was 
used for all analyses based on the DerSimonian and 
Laird approach.22 Analyses were conducted in Review 
Manager 5.3.
Time and predication intervals—Outcomes were 
assessed at 1, 3, 6, and 12 months post-randomisation, 
and data were analysed according to the time closest 
to these intervals. The primary outcomes were defined 
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as short term (one month), intermediate term (six 
months), and long term (12 months). We extracted the 
three month data for meta-analyses but these are not 
reported here. Additionally, we calculated prediction 
intervals for the outcomes. These intervals represent 
the expected range of true effects in similar studies and 
reflect the variation in treatment effects over different 
settings, including what effect is to be expected in a 
future trial.23
Assessment of clinical relevance—Clinical relevance 
was defined as small: mean difference <10% of the 
scale (eg, <10 mm on a 100 mm visual analogue 
scale) or SMD ≤0.5; medium: mean difference 10-20% 
of the scale or SMD ranging from 0.5 to 0.8; large: 
mean difference >20% of the scale or SMD ≥0.8. The 
determination of clinical relevance originates from the 
behavioural sciences.24 These three levels are broadly 
used across systematic reviews and are recommended 
by the Cochrane Back and Neck Review Group, which 
included consumer/patient representatives.25
Unit of analysis issues—When multiple contrasts from 
the same trial were examined in the same comparison, 
we halved the number of participants in the shared 
comparison. This step accounts from problems arising 
when multiple arms from the same trial are examined 
in the same meta-analysis. “Halving” the number of 
participants corrects for error introduced by double 
counting.21
Dealing with missing data—When it was not possible 
to extract metadata from a publication, we used 
individual patient data if available. The research team 
has received these data from most studies published 
since 2000 for an individual patient data meta-
analysis that we are currently conducting. In all other 
cases, we attempted to contact the author if data were 
missing. If no response was received, we followed the 
guidelines as outlined in the Cochrane Handbook 
(section 7.7.3).21
Assessment of reporting biases—Funnel plots were 
constructed, where possible, to explore publication 
bias. Additionally, we examined potential conflicts of 
interest as well as the funding source.
Data synthesis—GRADE was used to evaluate the 
overall quality of the evidence for each outcome, which 
ranges from high to very low quality and is based on 
five domains: limitations of design, inconsistency of 
results, indirectness, imprecision, and other factors, 
such as publication bias. Appendix 3 describes the 
criteria and operational definitions.
Assessment and investigation of heterogeneity—A 
prerequisite to pooling data was based on clinical 
homogeneity, which is why we stratified the meta-
analyses by type of comparison, outcome, and time 
interval. Statistical heterogeneity was examined by 
inspecting the Forest plot and was formally tested 
using the Q test (χ2) and I2. We attempted to explain 
cases of considerable heterogeneity (defined as an 
I2 statistic ≥75%) using meta-regression for those 
comparisons with sufficient data. The following 
variables were considered a priori: duration of the 
low back pain (subacute or chronic versus exclusively 
chronic), type of clinician (chiropractor versus other), 
type of radiating pain (above knee versus below knee); 
multimodal SMT (ie, SMT delivered alone compared 
with examined in a larger, multimodal context or as a 
package of care), and type of technique (HVLA versus 
LVLA). After examining the discriminative ability of 
these variables, we considered the additional variable 
of country where the study was conducted. Ultimately, 
we modelled just four variables: duration of the low 
back pain, type of clinician, multimodal SMT, and 
country. In the first step we conducted a univariate 
analysis and in a subsequent step we used the two 
variables showing the strongest effect to construct the 
final model. We report the effect and I2 for the final 
models only. These analyses were conducted in STATA, 
version 14.1.
Sensitivity analyses—Sensitivity analyses were 
planned a priori to determine the robustness of the 
data for risk of bias items (selection bias, performance 
bias, attrition bias, and selective outcome reporting 
bias), and by type of contrast (SMT versus exercise 
therapy). Among the risk of bias items we focused 
on selection bias, specifically treatment allocation, 
because this criterion showed exaggerated intervention 
effect estimates in a meta-analysis, which included a 
large collection of randomised trials published in the 
Cochrane Library.26
Patient and public involvement
No public or patient representatives were directly 
involved in the draft or process of this review. 
However, the primary outcomes examined in this 
review represent a core set recommended for low back 
pain, which included patient representatives in its 
development.
Results
In total, 47 trials fulfilled the inclusion criteria, 21 of 
which were not included in the previous review (fig 
1).14 27-72
Included studies
The countries in which the studies were conducted 
varied. Fifteen studies were conducted in the United 
States,14 28 29 33 34 40 41 44 45 46 49 54 66 70 72 seven in 
the United Kingdom,32 35 38 39 50 69 73 three each in 
Finland,42 52 71 Australia,36 51 67 and Italy,31 55 65 two each 
in Sweden,57 61 Denmark,53 56 Egypt,58 60 and India,59 64 
and one each in Belgium,43 Spain,30 Switzerland,27 
the Netherlands,47 Greece,48 Turkey,63 Pakistan,68 and 
Tunisia.37 All trials were published in English except 
the trial conducted in Tunisia, which was published in 
French. A detailed description of the characteristics of 
the included studies is available on request from the 
primary author. In total, 9211 patients were examined. 
Study sample sizes ranged from 21 to 1334 (median 
132, interquartile range 64-240).
Study population
Most studies included middle aged participants 
(on average, 35-60 years of age) with or without 
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radiating pain. Less than half of the studies examined 
those with exclusively chronic low back 
pain27 30 31 32 34 36 39 40 41 48 49 50 51 56 58 59 63 64 65 69 72; 
however, among those studies that recruited a mixed 
population, the duration of the pain typically ranged 
from months to years (see table A in appendix 5). 
None of the studies made a clear distinction between 
persistent low back pain or exacerbation of a chronic 
condition.
Provenance of evidence
We would have liked to have described whether the 
research team was multidisciplinary and whether it 
included clinicians who were involved in the treatment, 
but in many cases these data were not reported. 
Importantly, no official disclosure was reported in most of 
the studies, although many were older studies for which 
disclosure was not standard procedure at the time.
Primary investigators
Affiliations—The primary investigators were affiliated 
with a department of physiotherapy or osteopathy 
within a university setting,14 27 30 33 36 49 57 58 59 63 64 65 72 
health sciences department or similar within a 
university setting,29 41 43 46-48 51-54 61 62 67 71 department 
of medicine, rheumatology, or similar,35 37 38 50 55 56 60 68 
chiropractic based research department,28 34 40 44 45 66 70 
or clinician initiated (independent of a university or 
college)31 32 39 42 69
Qualifications—The primary investigators 
(excluding potential training as a researcher, PhD) 
were trained as chiropractor,28  29  34  40  41  44-46  51  67  69 
physical/manual therapist,14 30 33 36 43 52 53 57 68 
osteopath,49 72 medical doctor,31 35 37 38 42 50 55 60 62 71 or 
naturopathist,61 and some had no training as therapist 
or clinician39 47 54 59 70 or qualifications were unknown 
or unclear.27 32 48 56 58 63 64 65 66
Additional records identified
through trial registry searches
Full text articles excluded
Did not evaluate spinal manipulative therapy
Not randomised trial
Contribution of spinal manipulative therapy to
  treatment effect not clear
No relevant outcome for this review or evaluated
  immediate effects of treatment only
Evaluated exclusively sciatica
Evaluated predominately subjects with acute or
  subacute lower back pain
Duration of lower back pain unclear
No relevant study population
Congress proceedings, “grey literature”, or
  unpublished thesis
7
3
4
6
1
6
3
9
3
Records identified
411
Records identified through database
searching (June 2009 to May 2018)
Duplicates removed
Records screened
Studies included in qualitative synthesis
47
Studies included in quantitative synthesis (meta-analysis)
41
42
Full text articles assessed for eligibility
63
4184
New studies included in updateArticles identified by
expert suggestion
Studies included in
previous version of review
1540
Records excluded
2992
3055
4595
0 2126
Fig 1 | Selection of studies through review
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Involvement in treatment—In four studies the primary 
investigator was involved in treatment,14  43  52  68 in 
nine not involved,27-31 33-36 38-42 44-47 49 50 53-55 61-63 66 67 70-73 
and in the remainder it was unknown or 
unclear.32 37 48 51 56-60 64 65 69
Funding and competing interests
Fifteen of the studies were funded by 
government,27 29 30 32 38 41 42 44 47 50 51 62 63 69 70 12 by a 
private or professional organisation,28 31 39 49 53-57 66 67 71 
and eight by a combination of these.14 34 36 40 45 46 61 72 
In 12 studies funding was not reported or was 
unclear.33 35 37 43 48 52 58-60 64 65 68
In 16 studies the authors declared no competing 
interests,14 27 29 30 31 34 41 43 48 53 60-62 67 68 70 and in 
the remainder no official disclosure was 
reported28 32 33 35 36 37 39 40 42 44 45 46 47 49-52 54-59 63-66 69 71 72 74
Types of technique and practitioner
Practitioners—In 16 studies treatment was delivered by 
a chiropractor,28 29 34 40 41 44 45 46 51 53-55 66 67 69 70 in 14 by 
a manual or physical therapist,27 30 33 36 39 43 47 48 50 57-59 63 64 
Table 1 | Summary of treatment effects and GRADE summary of findings for all comparisons among trials included in 
systematic review of spinal manipulative therapy (SMT) for chronic low back pain
Analyses Effect estimate* (95% CI) No of studies No of participants I2 (%)
Quality of evidence  
(reason for downgrading)
Primary analyses
SMT versus recommended therapies
Pain:
 1 month −3.17 (−7.85 to 1.51) 17 3155 92 Moderate (inconsistency)
 6 months −3.09 (−5.42 to −0.77) 11 2462 58 Moderate (inconsistency)
 12 months −1.86 (−4.79 to 1.07) 10 2502 69 Moderate (inconsistency)
Functional status:
 1 month −0.25 (−0.41 to −0.09) 16 3090 76 Moderate (inconsistency)
 6 months −0.09 (−0.21 to 0.03) 12 2672 50 Moderate (inconsistency)
 12 months −0.09 (−0.23 to 0.04) 11 2635 62 Moderate (inconsistency)
SMT versus non-recommended therapies
Pain:
 1 month −7.48 (−11.50 to −3.47) 8 991 55 High
 6 months −7.54 (−13.29 to −1.79) 4 372 35 Moderate (imprecision)
 12 months −7.80 (−14.19 to −1.41) 1 169 0 Low (inconsistency, imprecision)
Functional status:
 1 month −0.41 (−0.67 to −0.15) 7 835 67 High
 6 months −0.29 (−0.50 to −0.09) 4 373 0 Moderate (imprecision)
 12 months −0.42 (−0.72 to −0.11) 1 169 100 Low (inconsistency, imprecision)
SMT versus sham SMT
Pain:
 1 month −7.55 (−19.86 to 4.76) 8 831 96 Low (limitations, inconsistency)
 6 months 0.96 (−6.34 to 8.26) 2 114 35 Very low (limitations, inconsistency, 
imprecision)
 12 months 0.20 (−5.33 to 5.73) 1 63 0 Very low (limitations, inconsistency, 
imprecision)
Functional status:
 1 month −0.73 (−1.35 to −0.11) 6 748 91 Low (limitations, inconsistency)
 6 months −0.12 (−0.50 to 0.25) 2 114 0 Very low (limitations, inconsistency, 
imprecision)
 12 months −0.19 (−0.69 to 0.31) 1 63 0 Very low (limitations, inconsistency, 
imprecision)
SMT as adjuvant therapy
Pain:
 1 month −6.93 (−10.36 to −3.49) 6 1046 41 Moderate (limitations)
 6 months −6.77 (−14.07 to 0.53) 2 143 0 Low (limitations, imprecision)
 12 months −3.31 (−6.60 to −0.02) 2 1000 12 Moderate (limitations)
Functional status:
 1 month −0.29 (−0.55 to −0.03) 4 955 62 Moderate (limitations)
 6 months −0.30 (−0.64 to 0.03) 2 142 0 Low (imprecision, inconsistency)
 12 months −0.21 (−0.34 to −0.09) 1 994 0 Low (imprecision, inconsistency)
Secondary analyses
HVLA SMT versus LVLA SMT
Pain:
 1 month 0.32 (−3.05 to 3.69) 4 509 0 Moderate (inconsistency)
 6 months No data available – – – –
 12 months No data available – – – –
Functional status:
 1 month 0.16 (−0.42 to 0.74) 4 520 90 Low (inconsistency–two levels)
 6 months 0.16 (−0.14 to 0.46) 1 175 0 Low (limitations, imprecision)
 12 months No data available – – – –
HVLA=high velocity, low amplitude; LVLA=low velocity, low amplitude.
*Data are mean differences for pain and standardised mean differences for functional status.
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in six by a medical manipulator or orthomanual 
therapist,31 35 52 56 60 68 in five by an osteopath,32 38 49 65 72 
in two by a bonesetter,42 71 in one by a naprapath,61 
and in one by several different disciplines.73 In another 
study, it was unclear what type of SMT treatment was 
delivered or the level or skill of the treating clinicians.37 
In virtually all studies, experienced clinicians or 
therapists delivered the treatment, with the exception 
of one study where treatment was delivered by a few 
predoctoral osteopathic fellows.49
Techniques—Three types of primary technique 
were used in the SMT arm of the studies: high 
velocity, low amplitude (HVLA) thrust 
SMT,14  28  29  33  35  44  45  50  51  53-56  59  60  65  66  70 low velocity, 
low amplitude (LVLA) passive movement 
techni ques,33  40  42  43  44  48  57  58  64  68  70  71 or a 
combina tion (HVLA manipulation and LVLA 
mobilisation).27 30 31 32 34 36 38 39 41 46 47 49 52 53 61 62 63 65 69 72 
In one study, the technique used was unclear,37 and 
in four studies, HVLA SMT was compared with LVLA 
SMT.30 33 44 70
Risk of bias in included studies
Three studies were identified as having a 
major flaw and were excluded from the meta-
analyses.32 39 51 Less than half of the studies (45% 
(n=21/47)) used both an adequate sequence 
generation and an adequate allocation 
procedure.27-31  34  36  40  41  42  44  47  53  61  63  67  69  70  71  73  75 
Five studies (10% (n=5/47)) attempted to blind 
patients to the assigned intervention by providing 
a sham treatment,37 49 60 66 72 while in one study 
it was unclear.58 More than half of the studies 
(57% (n=27/47)) provided an adequate overview 
of withdrawals or drop-outs and kept these to a 
minimum.14 27 29 30 31 33-38 41-43 45 47 48 54 59 61 65 67 69-72 75 
Less than one third of the studies (30% (n=14/47)) 
published or registered the protocol, and the 
reported outcomes were consistent with the 
protocol.14 29 30 36 41 43 44 48 53 61-63 71 72 Appendix 4 
summarises the risk of bias assessments.
Effects of interventions
Table 1 summarises the treatment effects and quality 
of the evidence for all comparisons.
Primary analyses
SMT versus recommended interventions
Twenty six studies compared the effects of SMT with 
recommended interventions.28 29 31 32 34 36 39 40 42 44 45 47 
48 51-53 55 57 59 61 62 63 68 69 71 75 Data could not be extracted 
from five studies,32 39 47 51 55 three of which had a major 
flaw.
Pain—Moderate quality evidence suggested that SMT is 
not statistically better than recommended interventions 
at one month and 12 months, although the difference 
was significant at six months. The size of the effect was, 
however, not clinically relevant (fig 2). Exclusion of 
extreme outliers accounted for a large percentage of the 
statistical heterogeneity for this outcome at one month 
(mean difference −0.39, 95% confidence interval −2.41 
to 1.62; participants=3005; studies=23; I2=44%), while 
the overall effect remained virtually unchanged.
Back specific functional status—Moderate quality 
evidence suggested that SMT results in a small, 
statistically better effect than recommended 
interventions at one month but not statistically better 
effect at six and 12 months (fig 3). Exclusion of extreme 
outliers accounted for a large percentage of the 
statistical heterogeneity for this outcome at one month 
(SMD −0.12, 95% confidence interval −0.23 to −0.01; 
participants=2907; studies=22; I2=44%), while the 
overall effect remained virtually unchanged.
SMT versus non-recommended interventions
Eleven studies compared the effects of SMT with non-
recommended interventions.14 27 38 41 45 47 50 54 55 67 70 
Data could not be extracted from three studies.47 54 55
Pain—High quality evidence suggested that SMT 
results in a small, statistically significant but not 
clinically better effect than non-recommended 
interventions at one month. Moderate quality evidence 
suggested that SMT results in a statistically significant 
but not clinically better effect at six months, and low 
quality evidence that SMT results in a statistically 
significant but not clinically better effect at 12 months 
(fig A in appendix 5).
Back specific functional status—High quality evidence 
suggested that SMT results in a small to moderate 
statistically and clinically better effect than non-
recommended interventions at one month. Moderate 
quality evidence suggested that SMT results in a small, 
statistically significant and clinically better effect at six 
months, and low quality evidence that SMT results in a 
small to moderate, statistically significant and clinically 
better effect at 12 months (fig B in appendix 5).
SMT versus sham SMT
Seven studies compared the effect of SMT with sham 
SMT.14 37 43 49 60 66 72
Pain—Low quality evidence suggested that SMT 
does not result in a statistically better effect than sham 
SMT at one month. Exclusion of an extreme outlier 
accounted for a large percentage of the statistical 
heterogeneity for this outcome at this time interval 
(mean difference −3.49, 95% confidence interval 
−6.03 to −0.94; participants=781; studies=9; I2=5%), 
while the overall effect remained virtually unchanged. 
Additionally, very low quality evidence suggested that 
SMT does not result in a statistically better effect than 
sham SMT at six and 12 months (fig C in appendix 5).
Back specific functional status—Low quality 
evidence suggested that SMT results in a moderate 
to strong statistically significant and clinically better 
effect than sham SMT at one month. Exclusion of an 
extreme outlier accounted for a large percentage of the 
statistical heterogeneity for this outcome at this time 
interval (SMD −0.27, 95% confidence interval −0.52 
to −0.02; participants=698; studies=7; I2=39%), 
resulting in a small, clinically better effect in favour of 
SMT. Additionally, very low quality evidence suggested 
that SMT does not result in a statistically significant 
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Pain at 1 month
  Bronfort 2011
  Bronfort 2011
  Brønfort 1996 
  Cecchi 2010 
  Cecchi 2010 
  Dougherty 2014 
  Dougherty 2014 
  Gudavalli 2006 
  Hemmila 2002 
  Hemmila 2002 
  Hondras 2009
  Hondras 2009
  Hsieh 2002 
  Hurwitz 2002
  Hurwitz 2002
  Krekoukiasa 2017 
  Rasmussen-Barr 2003
  Sarker 2017 
  Skillgate 2007 
  UK BEAM trial 2004 
  Ulger 2017 
  Waqqar 2016 
  Wilkey 2008 
Subtotal
Test for heterogeneity: τ2=112.20; χ2=282.66, df=22, P<0.001; I2=92%
Test for overall effect: z=1.33, P=0.18
Pain at 6 months
  Bronfort 2011 
  Bronfort 2011 
  Cecchi 2010 
  Cecchi 2010 
  Dougherty 2014 
  Dougherty 2014 
  Ferreira 2007 
  Gudavalli 2006 
  Hemmila 2002 
  Hemmila 2002
  Hsieh 2002
  Hurwitz 2002 
  Hurwitz 2002
  Paatelma 2008
  Paatelma 2008
  Petersen 2011
  Zaproudina 2009  
Subtotal
Test for heterogeneity: τ2=12.09; χ2=38.21, df=16, P=0.001; I2=58%
Test for overall effect: z=2.61, P=0.009
Pain at 12 months
  Bronfort 2011 
  Bronfort 2011 
  Cecchi 2010 
  Cecchi 2010 
  Ferreira 2007 
  Gudavalli 2006 
  Hurwitz 2002 
  Hurwitz 2002 
  Paatelma 2008 
  Paatelma 2008 
  Petersen 2011 
  Rasmussen-Barr 2003 
  UK BEAM trial 2004 
  Zaproudina 2009 
Subtotal
Test for heterogeneity: τ2=19.44; χ2=42.35, df=13, P<0.001; I2=69%
Test for overall effect: z=1.25, P=0.21
 2.00 (-4.16 to 8.16)
 3.00 (-3.40 to 9.40)
-2.00 (-10.10 to 6.10)
 3.30 (-4.04 to 10.64)
 5.00 (-2.34 to 12.34)
 8.30 (-3.23 to 19.83)
 1.00 (-15.03 to 17.03)
-6.00 (-11.50 to -0.50)
 3.50 (-4.54 to 11.54)
 0.50 (-7.50 to 8.50)
 -5.84 (-16.25 to 4.57)
 -3.98 (-14.33 to 6.37)
 4.50 (-2.34 to 11.34)
 -2.00 (-6.05 to 2.05)
 -4.00 (-8.06 to 0.06)
-37.60 (-43.15 to -32.05)
 4.00 (-10.12 to 18.12)
-19.40 (-22.52 to -16.28)
-8.00 (-12.16 to -3.84)
 0.06 (-3.65 to 3.77)
-0.20 (-5.42 to 5.02)
 10.80 (-3.43 to 25.03)
-27.20 (-44.35 to -10.05)
-3.17 (-7.85 to 1.51)
2.00 (-6.19 to 10.19)
4.00 (-4.18 to 12.18)
-10.00 (-15.83 to -4.17)
-10.00 (-15.55 to -4.45)
-4.90 (-18.35 to 8.55)
-3.60 (-14.11 to 6.91)
-2.60 (-10.00 to 4.80)
-7.10 (-13.69 to -0.51)
-1.00 (-9.04 to 7.04)
-5.00 (-13.00 to 3.00)
1.10 (-8.47 to 10.67)
-2.50 (-6.60 to 1.60)
-4.00 (-8.16 to 0.16)
4.00 (0.13 to 7.87)
-8.00 (-14.62 to -1.38)
0.10 (-2.66 to 2.86)
-6.80 (-15.90 to 2.30)
-3.09 (-5.42 to -0.77)
5.00 (-3.85 to 13.85)
5.00 (-3.19 to 13.19)
-15.00 (-20.67 to -9.33)
-10.00 (-15.72 to -4.28)
-1.60 (-9.41 to 6.21)
-2.40 (-8.80 to 4.00)
-1.50 (-5.76 to 2.76)
-0.50 (-4.78 to 3.78)
3.00 (-4.39 to 10.39)
-5.00 (-13.48 to 3.48)
1.30 (-1.63 to 4.23)
5.00 (-7.92 to 17.92)
0.14 (-4.61 to 4.89)
-4.10 (-13.80 to 5.60)
-1.86 (-4.79 to 1.07) 
-15 -10 -5 5 100 15
Study
Favours spinal
manipulative
therapy
Favours
recommended
therapies
Mean difference, IV
random (95% CI)
Mean difference, IV
random (95% CI)
39.0
39.0
34.0
20.0
20.0
34.9
37.5
17.4
30.5
30.5
27.63
29.49
25.8
34.0
31.0
12.0
24.0
20.3
36.0
48.99
20.8
25.5
42.8
33.0
33.0
13.3
13.3
47.6
38.5
43.0
19.7
25.0
25.0
24.0
26.0
18.0
14.0
14.0
15.4
24.5
33.0
33.0
11.7
11.7
49.0
20.9
32.5
27.5
11.0
11.0
15.9
18.0
41.68
26.6
Mean
18.0
18.0
19.0
20.0
20.0
31.2
28.9
22.3
15.0
15.0
19.31
19.29
19.3
19.0
18.0
11.0
26.7
6.2
14.4
22.16
12.0
26.5
22.5
24.0
24.0
11.7
11.7
25.7
27.0
26.0
22.3
15.0
15.0
24.1
19.0
18.0
8.1
8.1
12.2
24.6
24.0
21.0
13.3
13.3
27.0
22.3
19.0
18.0
14.1
14.1
13.5
21.5
25.67
26.2
SD
50
50
62
35
35
60
32
123
22
22
83
90
45
169
169
25
19
35
92
316
57
20
18
1629
46
46
35
35
32
60
72
90
22
22
40
165
163
23
23
161
57
1092
40
40
35
34
73
96
153
156
23
23
163
14
264
50
1164
Total No
4.7
4.6
4.4
4.5
4.5
3.9
3.2
4.7
4.4
4.4
4.1
4.1
4.6
4.9
4.9
4.7
3.5
5.0
4.9
4.9
4.8
3.5
3.0
100.0
4.8 
4.8
6.7
7.0
2.4
3.4
5.3
6.0
4.9
4.9
3.9
8.5
8.5
8.8
6.0
10.0
4.2
100.0
5.6
6.0
8.0
8.0
6.3
7.4
9.2
9.2
6.6
5.8
10.3
3.5
8.8
5.1
100.0
Weight
(%)
Spinal manipulative therapy
37.0
36.0
36.0
16.7
15.0
26.6
36.5
23.4
27.0
30.0
33.47
33.47
21.3
36.0
35.0
49.6
20.0
39.7
44.0
48.93
21.0
14.7
70.0
31.0
29.0
23.3
23.3
52.5
42.1
45.6
26.8
26.0
30.0
22.9
28.5
22.0
10.0
22.0
15.3
31.3
28.0
28.0
26.7
21.7
50.6
23.3
34.0
28.0
8.0
16.0
14.6
13.0
41.54
30.7
Mean
18.0
20.0
22.0
13.3
13.3
33.5
33.8
20.7
15.0
15.0
19.49
19.49
12.8
19.0
20.0
8.9
17.8
7.1
13.4
21.49
16.0
17.3
24.1
21.0
21.0
18.3
16.7
27.2
31.8
26.0
20.7
15.0
15.0
19.8
19.0
20.0
7.4
17.8
13.4
25.6
22.0
23.0
15.0
15.0
28.5
20.7
19.0
20.0
17.0
19.3
13.5
13.3
26.02
23.9
SD
95
96
43
68
68
61
28
112
34
35
16
16
42
169
168
25
22
35
80
228
56
17
12
1526
89
90
68
68
28
61
139
74
34
35
42
165
159
52
37
169
60
1370
81
82
68
68
138
78
153
148
52
37
163
17
200
53
1338
Total No
Recommended therapies
Fig 2 | Mean difference in reduction of pain at 1, 3, 6, and 12 months (0-100; 0=no pain, 100 maximum pain) for spinal manipulative therapy (SMT) 
versus recommended therapies in review of the effects of SMT for chronic low back pain. Pooled mean differences calculated by DerSimonian-Laird 
random effects model. See supplementary file for more detailed graphic
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0.02 (-0.32 to 0.36) 
0.00 (-0.34 to 0.34) 
-0.09 (-0.48 to 0.30) 
-0.89 (-1.32 to -0.47) 
-0.82 (-1.24 to -0.39) 
-0.07 (-0.58 to 0.43) 
0.18 (-0.17 to 0.54) 
-0.15 (-0.41 to 0.10) 
0.06 (-0.49 to 0.62) 
0.05 (-0.52 to 0.62) 
-0.61 (-1.15 to -0.08) 
-0.71 (-1.25 to -0.17) 
0.04 (-0.38 to 0.46) 
-0.09 (-0.30 to 0.12) 
-0.19 (-0.41 to 0.02) 
-2.55 (-3.32 to -1.79) 
0.47 (-0.15 to 1.10) 
-0.21 (-0.51 to 0.09) 
0.02 (-0.15 to 0.18) 
-0.33 (-0.70 to 0.04) 
0.14 (-0.51 to 0.78) 
-1.04 (-1.82 to -0.25) 
-0.25 (-0.41 to -0.09)
0.15 (-0.20 to 0.51) 
0.18 (-0.18 to 0.53) 
-0.68 (-1.10 to -0.26) 
-0.62 (-1.04 to -0.21) 
-0.02 (-0.37 to 0.34) 
-0.14 (-0.65 to 0.36) 
-0.24 (-0.53 to 0.04) 
-0.13 (-0.43 to 0.17) 
-0.15 (-0.69 to 0.39) 
0.09 (-0.45 to 0.63) 
-0.43 (-0.96 to 0.09) 
-0.29 (-0.81 to 0.23) 
-0.04 (-0.47 to 0.39) 
0.06 (-0.16 to 0.28) 
-0.12 (-0.34 to 0.09) 
0.00 (-0.52 to 0.52) 
0.33 (-0.16 to 0.82) 
0.24 (0.03 to 0.46) 
-0.22 (-0.58 to 0.15) 
-0.09 (-0.21 to 0.03)
0.27 (-0.11 to 0.65) 
0.21 (-0.17 to 0.59) 
-0.69 (-1.11 to -0.27) 
-0.65 (-1.07 to -0.23) 
0.00 (-0.28 to 0.28) 
-0.09 (-0.39 to 0.21) 
-0.18 (-0.72 to 0.36) 
0.17 (-0.38 to 0.71) 
0.04 (-0.19 to 0.26) 
-0.09 (-0.31 to 0.14) 
0.00 (-0.52 to 0.52) 
-0.66 (-1.16 to -0.16) 
0.26 (0.04 to 0.48) 
0.00 (-0.71 to 0.71) 
-0.13 (-0.30 to 0.05) 
-0.32 (-0.71 to 0.07) 
-0.09 (-0.23 to 0.04) 
-1.5 -1.0 -0.5 0.5 1.00 1.5
Study
Favours spinal
manipulative
therapy
Favours
recommended
therapies
Standardised
mean difference, IV
random (95% CI)
Standardised
mean difference, IV
random (95% CI)
5.9
5.9
19.1
1.6
1.6
29.0
26.7
3.8
16.7
16.7
4.62
4.35
4.42
6.8
6.5
2.44
12.0
1.9
6.75
18.9
7.05
8.16
4.9
4.9
2.7
2.7
23.2
30.2
7.7
2.8
14.3
14.3
3.44
4.06
3.29
3.8
4.1
1.0
1.0
8.0
12.2
5.1
5.1
2.5
2.5
9.2
2.7
15.3
15.3
6.2
6.6
0.0
0.0
7.6
8.0
5.15
12.5
Mean
4.9
4.9
19.3
2.6
2.6
14.7
15.1
4.7
11.6
11.6
2.91
2.9
4.92
5.6
5.0
1.76
4.4
2.45
5.0
13.4
5.835
6.27
5.2
5.2
3.4
3.4
15.7
15.7
6.2
4.7
11.6
11.6
4.39
4.36
4.73
5.0
5.6
3.0
3.0
6.3
12.1
4.9
4.9
3.6
3.6
6.6
4.7
11.6
11.6
5.0
5.6
1.5
1.5
6.7
9.6
4.79
11.0
SD
50
50
62
35
35
32
60
123
20
20
94
87
45
169
169
25
19
92
318
57
20
18
1600
46
46
35
35
60
32
72
90
22
22
86
89
41
163
165
23
23
161
57
1268
41
41
35
35
73
95
22
22
156
153
23
23
163
14
273
50
1219
Total No
5.2
5.2
4.9
4.6
4.6
4.1
5.1
5.8
3.8
3.7
3.9
3.9
4.6
6.0
6.0
2.7
3.4
5.5
6.3
5.0
3.3
2.6
100.0
5.6
5.7
4.7
4.7
5.6
3.7
6.9
6.6
3.4
3.4
3.5
3.6
4.6
8.3
8.4
3.6
3.8
8.3
5.5
100.0
6.1
6.1
5.5
5.5
7.7
7.4
4.1
4.1
8.7
8.7
4.3
4.5
8.8
2.8
9.6
5.9
100.0
Weight
(%)
Spinal manipulative therapy
5.8
5.9
20.8
5.3
5.3
30.2
23.7
4.5
16.1
16.2
6.42
6.42
4.26
7.3
7.5
8.76
9.0
2.4
6.67
23.5
6.24
14.36
4.2
4.0
5.8
5.4
23.5
32.7
9.3
3.4
15.9
13.4
5.34
5.34
3.48
3.5
4.8
1.0
0.0
6.5
14.5
3.8
4.1
5.7
5.3
9.2
3.1
17.2
13.7
6.0
7.1
0.0
1.0
5.9
8.0
5.74
16.0
Mean
4.7
4.4
17.8
4.7
5.2
17.7
17.1
4.4
7.7
9.5
2.91
2.91
3.52
5.6
5.4
2.96
7.4
2.28
4.88
14.2
5.89
5.03
4.2
4.9
5.0
4.7
19.0
18.6
6.7
4.4
9.5
7.7
4.27
4.27
3.86
5.4
5.6
5.2
3.0
6.0
8.9
4.7
4.7
5.0
4.6
6.7
4.4
9.5
7.7
5.4
5.6
2.2
1.5
6.2
5.9
4.56
10.7
SD
96
95
43
68
68
28
61
112
33
29
16
16
42
169
168
25
22
80
234
56
17
12
1490
89
90
68
68
61
28
139
78
33
33
17
17
42
159
165
37
52
168
60
1404
82
81
68
68
138
78
32
32
148
153
37
52
161
17
216
53
1416
Total No
Recommended therapies
Pain at 1 month
  Bronfort 2011
  Bronfort 2011
  Brønfort 1996 
  Cecchi 2010 
  Cecchi 2010 
  Dougherty 2014 
  Dougherty 2014 
  Gudavalli 2006 
  Hemmila 2002 
  Hemmila 2002 
  Hondras 2009
  Hondras 2009
  Hsieh 2002 
  Hurwitz 2002
  Hurwitz 2002
  Krekoukiasa 2017 
  Rasmussen-Barr 2003
  Skillgate 2007 
  UK BEAM trial 2004 
  Ulger 2017 
  Waqqar 2016 
  Wilkey 2008 
Subtotal
Test for heterogeneity: τ2=0.10; χ2=88.21, df=21, P<0.001; I2=76%
Test for overall effect: z=3.01, P=0.003
Pain at 6 months
  Bronfort 2011 
  Bronfort 2011 
  Cecchi 2010 
  Cecchi 2010 
  Dougherty 2014 
  Dougherty 2014 
  Ferreira 2007 
  Gudavalli 2006 
  Hemmila 2002 
  Hemmila 2002 
  Hondras 2009
  Hondras 2009
  Hsieh 2002
  Hurwitz 2002 
  Hurwitz 2002
  Paatelma 2008
  Paatelma 2008
  Petersen 2011
  Zaproudina 2009  
Subtotal
Test for heterogeneity: τ2=0.03; χ2=35.73, df=18, P=0.008; I2=50%
Test for overall effect: z=1.48, P=0.14
Pain at 12 months
  Bronfort 2011 
  Bronfort 2011 
  Cecchi 2010 
  Cecchi 2010 
  Ferreira 2007 
  Gudavalli 2006 
  Hemmila 2002 
  Hemmila 2002  
  Hurwitz 2002 
  Hurwitz 2002 
  Paatelma 2008 
  Paatelma 2008 
  Petersen 2011 
  Rasmussen-Barr 2003 
  UK BEAM trial 2004 
  Zaproudina 2009 
Subtotal
Test for heterogeneity: τ2=0.04; χ2=39.33, df=15, P<0.001; I2=62%
Test for overall effect: z=1.34, P=0.18
Fig 3 | Standardised mean difference for improvement in function at 1, 3, 6, and 12 months for spinal manipulative therapy (SMT) versus 
recommended therapies in review of the effects of SMT for chronic low back pain. Pooled standardised mean differences calculated by DerSimonian-
Laird random effects model. See supplementary file for more detailed graphic
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better effect than sham SMT at six and 12 months (fig 
D in appendix 5).
SMT as adjuvant therapy
Seven studies examined the adjuvant effects of SMT 
when combined with other therapies.35 45 49 56 64 65 73
Pain—Moderate quality evidence suggested that 
SMT results in a small, statistically significant but not 
clinically better effect at one month and 12 months, 
and low quality evidence that SMT does not result in a 
statistically better effect as an adjuvant therapy at six 
months (fig E in appendix 5).
Back specific functional status—Moderate quality 
evidence suggested that SMT results in a small, 
statistically significant and clinically better effect at 
one month, and low quality evidence that SMT results 
in a small, statistically significant and clinically better 
effect at 12 months, but not statistically significant 
effect at six months (fig F in appendix 5).
Secondary analyses
HVLA SMT versus LVLA SMT—Four studies examined 
the effect of HVLA SMT versus LVLA SMT.30 33 44 70 We 
found no statistically significant difference in effect 
between either technique for pain relief or improvement 
in function at one month (judged to be moderate and 
low quality, respectively). The evidence at six months 
was of low quality and there were no data for 12 months.
Mobilisation versus mobilisation—One small study 
with a high risk of bias for many criteria compared 
the effects of Maitland mobilisation with Mulligan 
mobilisation.58 The authors concluded that there was 
no significant difference between either technique for 
the short term reduction of pain.
Prediction intervals—Prediction intervals for the 
effect of SMT versus recommended therapies suggested 
a small to moderate effect in favour of either therapy, 
meaning that the therapy chosen by patients and 
clinicians should be based on factors other than 
effectiveness alone. Data were too few for the other 
comparisons to ascribe a meaningful interpretation to 
those results (table B in appendix 5).
Explanation of statistical heterogeneity and 
sensitivity analyses
We conducted meta-regression only for the comparison 
of SMT with recommended therapies. In general, two 
variables were typically included in the final model: 
multimodal SMT and duration of the low back pain 
(tables C and D in appendix 5). However, these variables 
did not explain the statistical heterogeneity for short 
term outcomes, and marginally for intermediate and 
long term outcomes. The moderator effects were also 
typically small and not clinically relevant. This meant 
that there was appreciably no difference in effect when 
SMT was offered as a package of care (as opposed to 
SMT alone) or when patients with exclusively chronic 
low back pain were included (as opposed to a mixed 
population). Meta-regression was not conducted for 
the other comparisons because data were too few to 
ascribe any meaningful interpretation to those results. 
Additionally, no appreciable difference was found in 
effects for risk of bias or when the effect of SMT versus 
exercise was examined.
Publication bias—Publication bias was only 
examined for SMT versus recommended therapies, 
owing to the paucity of data for the other comparisons. 
We constructed two separate funnels plots for pain and 
functional status for all time measurements (figs G and 
H in appendix 5). Although these funnel plots do not 
suggest publication bias, this cannot be ruled out.
Adverse events
About half of the studies examined adverse events 
(table 2).27-31 33-36 40 41 43 44 45 51 56 60 61 62 67 70-72 In most 
of these studies it was unclear how and whether 
adverse events were registered systematically 
29 30 33 34 61 62 67; therefore, these data might be unreliable 
and not accurate for incidence. However, one of the 
studies included in this review67 was a secondary 
analysis of a trial designed to examine the incidence 
of these events.76 That study (n=183) suggested no 
increased risk of an adverse event (relative risk 1.24, 
95% confidence interval 0.85 to 1.81) or severe adverse 
event (1.9, 0.98 to 3.99) compared with sham SMT.76 
Two studies reported serious adverse events34  72: in 
one the Data Safety Monitoring Board judged none of 
these events to be associated with SMT,34 and in the 
other the Data Safety Monitoring Board judged one 
event to be possibly related to SMT.72
Discussion
In the treatment of chronic low back pain in adults, 
moderate quality evidence suggests that spinal 
manipulative therapy (SMT) results in similar outcomes 
to recommended therapies for short, intermediate, 
and long term pain relief as well as improvement in 
function. In addition, the quality of evidence varied 
suggesting that SMT does not result in clinically better 
effects for pain relief but does result in clinically better 
short term improvement in function compared with 
non-recommended therapies, or sham, and when 
included as an adjuvant therapy.
Most studies examined the effect of SMT in a 
pragmatic setting and might therefore be considered 
the most robust evidence. Given the considerable data 
available, we can now calculate within reasonable 
certainty the effect of SMT in this setting as well 
as the impact of a future, methodologically well 
conducted trial (as determined by the prediction 
intervals). Evidence for the remaining comparators 
was considered to be of moderate quality or lower 
(with the exception of the short term effect of SMT 
versus non-recommended therapies), suggesting some 
uncertainty around these effect estimates. However, it is 
questionable whether additional studies are necessary, 
and it is debatable whether studies that examine the 
effect of SMT compared with non-recommended 
therapies or sham (placebo) therapies will add further 
to our understanding. In fact, during this update we 
identified several, recent small pragmatic studies 
with a high risk of bias.48 58 59 63 68 This is of concern 
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Table 2 | Summary of adverse event assessments among trials included in systematic review of spinal manipulative therapy (SMT) for chronic low back 
pain
Study, sample size
Methods used  
to assess  
adverse events Adverse events assessed Adverse events reported (for SMT or control group)
Balthazard 2012, n=42 Not reported Any adverse event No adverse events reported; but one patient dropped out in each group owing to severe pain
Bronfort 2011, n=301 Self reported throughout 
follow-up
Any adverse event “All adverse events were transient in nature, required little or no change to activity levels, and 
were considered non-serious,” 6 (2%) patients were treated with rescue pain medication dur-
ing treatment period: severe back pain, acute flare-up of low back and buttock pain, neck pain, 
and inability to sleep because of pain. Four (1%) patients reported similar adverse events but 
declined rescue medication
Brønfort 1996, n=174 Not reported Any adverse event Non-steroidal anti-inflammatory drug group: 2 (4%) patients developed severe nausea and 
vomiting and subsequently discontinued the study, 8 (16%) developed substantial nausea 
and dyspepsia, and 1 (2%) developed severe tinnitus; SMT+exercise groups: 1 (2%) patient 
discontinued exercise because she did not tolerate it well and 7 (14%) developed muscle 
soreness and stiffness, including neck pain after exercise—these symptoms gradually abated 
and did not prevent completion of the study; 1 (1%) developed symptoms of a myocardial 
infarction unrelated to exercise. “Overall, both strengthening and stretching exercise and SMT 
were well tolerated”
Castro-Sanchez 2016, 
n=62
Self reported after treat-
ment and follow-up
Any adverse event No adverse events reported
Cecchi 2010, n=210 Not reported Any adverse event No adverse events reported
Cook 2013, n=154 Physiotherapists queried 
at end of study
Any adverse event No adverse events reported
Dougherty 2014a, 
n=181
Assessed at each  
treatment visit and 
via phone calls during 
follow-up period
Any adverse event 243 adverse events were reported during the study: 55% in exercise group and 45% in SMT 
group. Of 110 events reported in the SMT group, the Data Safety Monitoring Board (DSMB) 
judged 14 as definitely or probably associated with SMT. Most adverse events consisted of 
musculoskeletal soreness and resolved within study period. During the study period, 10 
serious adverse events were reported (5 control group, 5 SMT group); DSMB judged none of 
the serious adverse events to be associated with the study intervention
Evans 1978, n=36 Not reported Any adverse event 1 (3%) patient reported constipation after consumption of 24 codeine phosphate capsules in 
first 4 days; no serious adverse events reported
Ferreira 2007, n=240 Not reported Any adverse event No adverse events reported, one patient died, and one was admitted to hospital, in control 
group
Gudavalli 2006, n=235 Not reported Any adverse event No adverse events reported
Haas 2014, n=400 Not reported Any adverse event 3 (1%) patients reported seeking care for symptomatic relief of low back pain exacerbation 
related to study, 1 (1%) lost several days of work followed by complete resolution during 
treatment phase, and 1 (1%) dropped out after an exacerbation associated with lifting a child; 
no serious adverse events reported
Hidalgo 2015, n=32 Not reported Any adverse event No serious or moderate adverse events reported
Hondras 2009, n=240 Not reported Any adverse event 20 (8%) patients reported an adverse event, all resolved within 6 days, and none required 
referral for outside care. Adverse events in SMT groups consisted of soreness or stiffness. 1 
patient reported a skin rash in drug group; no serious adverse events reported
Hsieh 2002, n=206 Not reported Any adverse event 23 (12%) patients reported adverse events: 17 (11%) in control groups (combined), 6 (12%) 
in SMT group; adverse events were limited to transient exacerbations of symptoms, except for 
one case of constant tinnitus in a control group; 2 (4%) patients claimed SMT had aggravated 
their condition; no serious adverse events reported
Licciardone 2013,  
n=455
Not reported Any adverse event 27 (6%) patients reported an adverse event; 9 (2%) reported a serious adverse event (“none 
was definitely or probably related to a study intervention” according to DSMB); no significant 
differences between groups in frequency of (serious) adverse events; 6 patients who received 
SMT developed a contraindication to continued study participation (SMT was adjudicated by 
DSMB to be possibly related to development in only one of these)
Muller 2005, n=115 Not reported Any adverse event 3 (6%) patients in drug group experienced an adverse event; no serious adverse events 
reported
Rasmussen 2008,  
n=72
Not reported Any adverse event 4 (11%) patients in SMT group reported worsening of low back pain versus 3 (8%) in control 
group; no serious adverse events reported
Senna 2011, n=93 Not reported Any adverse event Most common were local discomfort and tiredness, which were transient and began within 
24 hours after treatment, and were of mild to moderate severity; no serious adverse events 
reported
Skillgate 2007, n=409 Self-reported events at a 
follow-up visit
Any adverse event Minor short term events limited to muscle soreness, tiredness, and increased pain, most 
commonly after first and second treatments; no serious adverse events reported
UK BEAM trial 2004, 
n=1334
Monitoring by research 
team; not elucidated 
further
Serious adverse events only, 
defined as admission to  
hospital or death within one  
week of treatment
No serious adverse events reported
Walker 2013, n=183 Self-reported events at 
each follow-up visit
Any adverse event 30 (33%) of patients in sham group and 39 (42%) in SMT group reported at least 1 adverse 
event; common adverse events were increased pain (sham 29%; SMT 36%), muscle stiffness 
(sham 29%; SMT 37%), and headache (sham 17%; SMT 9%). The relative risk was not signif-
icant for adverse event occurrence (1.24, 95% confidence interval 0.85 to 1.81), occurrence 
of severe adverse events (1.9, 0.98 to 3.99), adverse event onset (0.16, 0.02 to 1.34), or 
duration of adverse events (1.13, 0.59 to 2.18); no serious adverse events reported
Xia 2016, n=192 Not reported Not reported No serious adverse events reported
Zaproudina 2009,  
n=131
Not reported Not reported 1 (2%) patient in SMT group and 2 (3%) in control group discontinued treatment owing to 
worsening of low back pain; no serious adverse events reported
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because these types of studies only weaken rather than 
strengthen the evidence and should be discouraged. 
Curiously, this finding contrasts with an earlier study 
that identified a trend towards better quality studies 
investigating SMT.77 Future studies should focus on 
identifying moderators likely to influence treatment 
effects (such as socioeconomic status, level of 
education), and this is a line of evidence that we are 
currently pursuing in an individual participant data 
meta-analysis.
We present average clinical effects for the groups. 
For a better interpretation of the results, benefit might 
arise if additional analyses are included in future 
trials, such as the proportion of patients achieving a 
clinically meaningful response. This could be obscured 
by group averages. Additionally, we can better interpret 
the effects if greater attention is paid to the qualitative 
components of interventions, such as the context of 
the visit, and patient beliefs and preferences.78
Comparison with other studies
Ostensibly, these results are consistent with our 
previous review.19 One major difference between the 
reviews was the classification of the comparator: in 
the first review we classified therapies into effective 
and non-effective, whereas in this review we classified 
them into recommended and non-recommended 
therapies. It was thought that this would best help 
the translation of findings to clinical practice. We 
based the classification of the comparator on recent 
guidelines, but this was not always clear because 
evidence among the different guidelines conflicted 
(eg, acupuncture), or a given therapy was not 
classified (eg, back school). We examined the impact 
of classifying these therapies with their opposing 
comparator in sensitivity analyses (data not shown), 
and this did not affect our results. Furthermore, our 
results are consistent with other recently published 
high quality systematic reviews79-81 and guidelines 
that recommend SMT.2 3 5
Implications for clinicians
SMT can be delivered as a standalone therapy, although 
it is typically offered within the constructs of a broader 
treatment package, together with exercise therapy 
or combined with usual care, as is recommended 
in recent national guidelines for low back pain.5 82 
This is important because SMT is by nature a passive 
treatment. Therefore, to prevent inappropriate 
behaviour and to empower patients to take control of 
their condition it is vital that practitioners impart the 
proper message to their patients.
The incidence of adverse events and serious adverse 
events based on the studies included here are difficult 
to assess because less than half of the randomised 
controlled trials examined these, and in most of the 
studies the methodology was unclear. Importantly, 
given the low incidence of serious adverse events, 
randomised controlled trials are not the design of 
choice. Based on a recent systematic review, serious 
adverse events after SMT for low back pain are thought 
to be rare and include case reports of cauda equina 
syndrome, fractures, and neurological or vascular 
compromise.83 A recent comprehensive scoping review, 
which examined the risks of manual treatments to the 
spine, identified 250 articles in which serious adverse 
events were reported. Most of these focused on adverse 
events after treatment to the neck.84 The body of 
evidence, which includes data from large, prospective 
observational studies of SMT, suggests that benign 
adverse events are common and serious adverse 
events are rare. The incidence and causal relations 
with serious adverse events are difficult to establish, 
in part due to inherent methodological limitations of 
the included studies. Importantly, predictors of these 
events are unclear. Given this, clinicians should ensure 
that patients are fully informed of potential risks before 
treatment.
Implications for policy makers and other 
researchers
Although we focused on the effects of SMT in this 
review, the costs associated with care should also 
be considered. The most recent systematic review 
on cost effectiveness of non-invasive and non-drug 
interventions for the treatment of low back pain 
concluded that manual treatments, including SMT 
and massage, should be considered a cost effective 
option.85 This conclusion, however, was based on 
10 studies, only two of which are included in this 
review.73 86 Another recent systematic review that 
focused on the effects of SMT for spinal pain concluded 
that SMT is a cost effective option when used alone or 
in combination with other treatments.87 However, this 
conclusion was based on six studies, including studies 
that examined the effect of SMT for the treatment of 
neck pain, and was limited to the same two studies 
cited previously. 73 86 To our knowledge, no other 
economic evaluations have been done of SMT for 
the treatment of chronic low back pain. Although we 
did not actively search for these types of evaluations 
because that was an objective of this review, it is 
unlikely we missed any economic evaluations in these 
studies. The primary author knows this literature well 
and regularly attends meetings in which trial results 
are presented. Furthermore, it is likely that studies as 
well as protocols would have referenced an economic 
evaluation if it existed. Therefore, it remains to be 
determined whether SMT is a cost effective option for 
the treatment of chronic low back pain.
Limitations of this study
The most important limitations are those inherent 
to most (if not all) systematic reviews—namely, the 
limited number of studies with a low risk of bias, as 
well as ambiguity about the impact of publication 
bias. Furthermore, we could not resolve the problem 
related to statistical heterogeneity nor is this likely 
to be resolved in future reviews: studies of SMT 
are conducted in varied settings, among different 
populations, using several methods of recruitment and 
SMT techniques that are subsequently compared with 
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various types of therapies. Finally, in most studies it 
was unclear if the research team was multidisciplinary, 
and whether it included clinicians involved in the 
treatment of patients, but perhaps most importantly, 
given that disclosure was often not reported, potential 
conflicts of interest cannot be ruled out.
Recommendations for future study
Future trials of SMT for low back pain should include 
an economic evaluation; an analysis of the proportion 
of patients who achieved a specified level of pain 
relief (eg, percentage of those experiencing 50% pain 
improvement); a better description of the qualitative 
components of SMT, such as the context of the visit, 
patient beliefs, and preferences, and also quantitative 
components, such as factors that are likely to influence 
treatment.
The evidence suggests that SMT results in a modest, 
average clinical effect at best: future trials on the effect of 
SMT for chronic low back pain are not necessary, unless 
they contain a novel approach, are well conducted, and 
address any of these specific recommendations.
Private or governmental agencies should refrain 
from funding small trials that are poorly conceived.
Conclusions
SMT produces similar effects to recommended therapies 
for chronic low back pain but results in clinically better 
effects for short term improvement in function compared 
with non-recommended therapies, sham therapy, or 
when added as an adjuvant therapy. Clinicians should 
inform their patients of the potential risks of adverse 
events associated with SMT.
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